HC Wainwright & Co. Maintains Buy on Roivant Sciences, Raises Price Target to $47

Benzinga Newsdesk www.benzinga.com Positive 70.5%

Neg 0% Neu 0% Pos 70.5%

HC Wainwright & Co. analyst Douglas Tsao maintains Roivant Sciences (NASDAQ:ROIV) with a Buy and raises the price target from $41 to $47.